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Abstract
Background: Aberrant activation of fibroblast growth factor receptor 3 (FGFR3) is frequently observed in bladder
cancer, but how it involved in carcinogenesis is not well understood. The current study was aimed to investigate
the underlying mechanism on the progression of bladder cancer.
Methods: The GSE41035 dataset downloaded from Gene Expression Omnibus was used to identify the differentially
expressed genes (DEGs) between bladder cancer cell line RT112 with or without depletion of FGFR3, and gene ontology
enrichment analysis was performed. Then, FGFR3-centered protein–protein interaction (PPI) and regulatory networks were
constructed. Combined with the data retrieved from GSE31684, prognostic makers for bladder cancer were predicted.
Results: We identified a total of 2855 DEGs, and most of them were associated with blood vessel morphogenesis and
cell division. In addition, KIAA1377, POLA2, FGFR3, and EPHA4 were the hub genes with high degree in the FGFR3-
centered PPI network. Besides, 17 microRNAs (miRNAs) and 6 transcriptional factors (TFs) were predicted to be the
regulators of the nodes in PPI network. Moreover, CSTF2, POLA1, HMOX2, and EFNB2 may be associated with the
prognosis of bladder cancer patient.
Conclusions: The current study may provide some insights into the molecular mechanism of FGFR3 as a mediator in
bladder cancer.
Keywords: Bladder cancer, Fibroblast growth factor receptor 3, Differentially expressed gene, Protein–protein
interaction network, Prognostic maker
Background
Bladder cancer, which refers to the cancer arising from
the epithelial lining of urinary bladder, is one of the most
frequent malignant cancers in the world. Its incidence
has steadily increased and ranked as the sixth most com-
mon form of cancer in 2013 [1]. Though not fully
known, the occurrence and development of bladder
cancer is closely associated with multiple environmental
factors, such as drinking, smoking, and contacting with
chemical products, as well as many genetic factors [2].
Fibroblast growth factor receptor 3 (FGFR3), which
belongs to the family of tyrosine kinase (RTK), is
responsible for the FGF signal transduction [3]. FGFR3
signaling plays regulatory roles in cell proliferation, dif-
ferentiation, and survival [4]. It is implicated in diverse
physiologic and pathologic processes. Previous study re-
vealed that FGFR3 is linked to the development of blad-
der cancer and FGFR3 overexpression and mutations are
frequent events in patients with bladder cancer [5].
Moreover, it has been proved that bladder cancer cell
proliferation in culture is inhibited when the activation
of FGFR3 was blocked [6]. There is no doubt that
FGFR3 takes vital roles in the process of tumorigenesis,
but how FGFR3 signaling contributes to carcinogenesis
is still unclear.
In current study, we reanalyzed the dataset GSE41035
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GS
E41035), which provided the gene expression profiles of
bladder cancer cell line RT112 with or without depletion
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of FGFR3, to identify the differentially expressed genes
(DEGs) upon loss of FGFR3 in bladder cancer. Based on
this dataset, Du et al. (another contributor of GSE41035)
have documented that FGFR3 can stimulate stearoyl
CoA desaturase 1 activity to promote bladder tumor
growth [7]. Protein–protein interaction (PPI) and regula-
tory networks related to FGFR3 were constructed to
investigate the possible mechanisms underlying the
oncogenic role of FGFR3 in bladder cancer. Besides, we
predicted the potential prognostic makers from the
DEGs in the FGFR3-centered PPI network for bladder




In current study, gene expression data of GSE41035
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GS
E41035) and GSE31684 [8] were downloaded from Gene
Expression Omnibus (GEO) database (http://www.ncb
i.nlm.nih.gov/geo/), respectively. Both of these two data-
sets were sequenced on [HG-U133_Plus_2] Affymetrix
Human Genome U133 Plus 2.0 Array. In GSE41035
uploaded by Modrusan et al., total of 24 cell samples, ran-
ging from GSM1007032 to GSM1007055, were included.
In this dataset, RT112 cells, a bladder cancer cell line,
were transduced with a doxycycline-inducible control
EGFP short hairpin (shRNA) or three independent FGFR3
shRNAs and then treated with or without doxycycline
for depletion of FGFR3 protein. Consequently, gene ex-
pression alterations induced by FGFR3 loss would be
identified by microarray analysis. The dataset GSE31684
uploaded by Riester et al. contained the gene expression
patterns associated with clinical and prognostic variables
of 93 bladder cancer patients managed by radical cystec-
tomy. For these 93 patients, the median ages were ranged
from 32.1 to 91.1 years and the male/female ratio was 68/
25. Meanwhile, 95% of them were transitional cell carcin-
oma (TCC), and the remains were TCC/squamous. In
addition, the radical cystectomy stages of them were 5
cases of pTa, 10 cases of pT1, 17 cases of pT2, 42 cases of
pT3, and 19 cases of pT4, and the follow-up times of them
were ranged from 1 to 175 months. This study was
approved by Memorial Sloan-Kettering Cancer Center In-
stitutional Review Board.
Data preprocessing and DEG identification
RankProd is a simple and rapid method for DEG identi-
fication, which is based on the rank of gene expression
and reliably utilized to explore difference of dataset with
small sample size. After normalized by robust multi-
array average (RMA) [9], the probe-level data in CEL
files were converted into expression measures. Then,
RankProd [10] was applied to identify the differentially
expressed genes between the FGFR3-depleted RT112
cells and the control cells. False discovery ratio (FDR)
<0.05 was set as the threshold.
GO functional enrichment analysis
Gene Ontology (GO) is a tool for functional annotation
of large-scale genomic data [11]. In the current study, we
used GO function [12] to identify the over-represented
GO biology processes among the DEGs. p value <0.05 was
chosen as cutoff criterion.
Construction of FGFR3-centered PPI network
The PPI data was collected from the Human Protein
Reference Database (HPRD) [13], a centralized resource
for information about human proteins, their interactions
with other human proteins, and protein–disease rela-
tionships. The PPI network was generated by mapping
the previously identified DEGs to the PPI data. FGFR3
was employed as a query node to construct the FGFR3-
centered PPI network. First, the direct interacting DEGs
with FGFR3 were selected, and then, the neighbors of
these DEGs were also selected. The subnetwork was
generated based on these proteins and visualized by
Cytoscape [14].
Construction of regulatory network
The experimentally validated dataset of human miR-
NAs/targets and transcriptional factors (TFs)/targets
were respectively retrieved from miRTarBase [15], a
database listing the miRNA–mRNA interactions col-
lected from the literatures in PubMed, and TRANSFAC
(TRANScription FACtor database) [16], a manually cu-
rated database of eukaryotic transcription factors, their
genomic binding sites, and DNA binding profiles. Based
on these two databases, miRNAs, which have regulatory
targets among DEGs, and TFs included in DEGs were
screened. The regulatory network associated with the
genes in the above sub-PPI network was constructed
using these data and visualized by Cytoscape [14].
Exploring the potential prognostic makers for bladder
cancer
The gene expression profiles and prognostic variables
were retrieved from GSE31684 [8]. According to the me-
dian expression values of the genes in FGFR3-centered
PPI network, patients with bladder cancer were divided
into high- and low-expression groups. Prognosis-related
genes were predicted by Cox regression model based on
univariate analysis and multivariate analyses. Survival
analysis was conducted by using the bioconductor
splines package and survival package in R. Log-rank test
was applied for comparison, and p value <0.05 was
chosen as the threshold.
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Results
Identification of DEGs
Genes that were differentially expressed after doxycyc-
line induction (FDR <0.05) in the control cell line were
considered as the DEG1 group, and those in 3 FGFR3-
depleted cell lines were considered as the DEG2 group.
Finally, we identified a total of 1428 upregulated and
1427 downregulated genes in the DEG2 group while
there were only 28 upregulated and 58 downregulated
genes in the DEG1 group.
GO enrichment analysis
To determine the potential processes mediated by the
DEG2 group, we separately mapped the upregulated and
downregulated to the GO BP database. With p value
<0.05 as the threshold, 5 GO terms were over-
represented by the upregulated genes (Table 1 (a)) and
the most significant one was regulation of transcription,
DNA dependent (GO:0006355) with p value = 1.50E−06.
The others were negative regulation of biological process
(GO:0048519, p value = 1.69E−06), response to type I
interferon (GO:0034340, p value = 1.42E−05), blood ves-
sel morphogenesis (GO:0048514, p value = 2.42E−05),
and epithelium development (GO:0060429, p value =
0.000125). However, 85 GO terms were enriched among
the downregulated genes. Table 1 (b) lists the top 5
terms, from which we found that these terms mainly
associated with cell division and carboxylic acid meta-
bolic process.
FGFR3-cented PPI network
The genes in DEG2 group were mapped to the PPI data
retrieved from the HPRD, and a network with 920 nodes
and 1514 edges were created. Then, 7 DEGs, which were
directly interacted with FGFR3, and other 31 inter-
actional DEGs neighboring of these 7 nodes were se-
lected to construct the FGFR3-centered PPI network
(Fig. 1). The top 5 genes with the greatest node degree
≥4 are listed in Table 2, which were KIAA1377, POLA2
(polymerase (DNA directed), alpha 2), FGFR3, EPHA4
(ephrin type A receptor 4), and KRT8 (keratin 8).
The regulatory network related to FGFR3
The potential regulatory miRNAs and TFs targeting to
the genes included in the FGFR3-centered PPI network
were screened out, and a regulatory network was con-
structed. There were 17 miRNAs/targets, and 8 TF/tar-
get regulatory relationships were predicted (Fig. 2).
Prediction of potential prognostic makers for bladder
cancer
Cox regression model was applied to identify the poten-
tial genes in the FGFR3-centered PPI network that were
associated with bladder cancer prognosis. HMOX2
(heme oxygenase-2), CSTF2 (cleavage stimulation factor,
3′ pre-RNA, subunit 2, 64 kDa), and POLA1 (polymer-
ase (DNA directed), alpha 1) were the three obviously
significant related genes, and a marginal significant cor-
relation was found between EFNB2 (ephrin-B2) and
prognosis of bladder cancer (Table 3). However, a multi-
variate analysis about these 4 genes showed that only
CSTF2 and EFNB2 were significant related to the recur-
rence of bladder cancer (p value = 0.005 and 0.030)
(Table 4). Moreover, the survival curves displayed in
Fig. 3 also obviously presented that patients with high
expression level of CSTF2 and POLA1 showed relative
favorable prognosis. However, HMOX2 and EFNB2 may
be the risk factors of bladder cancer. All of these results
might indicate that CSTF2 and EFNB2 were two import-
ant protective factors in the prognosis of bladder cancer.
Discussion
Bladder cancer is a complex process, implicated with
multiple genetic abnormalities. A body of studies evi-
denced that FGFR3 acts as an important oncogenic
driver in bladder cancer. Here, we explored the possible
mechanism how FGFR3 signaling mediates bladder can-
cer development and progression by bioinformatics
methods. We found that the expression levels of 2855
genes were altered upon the depletion of FGFR3 in blad-
der cancer cell line. These downregulated genes were
mainly involved in cell division and carboxylic acid
metabolic process while the upregulated were related to
blood vessel morphogenesis and response to type I
Table 1 The enriched biological processes by the differentially
expressed genes
GO term Biological process_name Count p value
a) Upregulated genes
“GO:0006355” “regulation of transcription,
DNA dependent”
260 1.50E−06
“GO:0048519” “negative regulation of
biological process”
282 1.69E−06










“GO:0007067” “mitosis” 132 0
“GO:0007346” “regulation of mitotic
cell cycle”
64 0




“GO:0051320” “S phase” 68 2.78E−12
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interferon. Increased cell division is a well-known cause
and essential for development and progression of human
cancer [17]. Adequate blood supply, such as angiogen-
esis, is also required for the growth and metastasis of
tumor [18]. Fibroblast growth factors (FGFs) and FGF
receptors can act as angiogenesis inducers and have con-
tribution to tumor vascularization [19]. Moreover, it has
shown that IFN-a, as one type of I interferon inhibits
the expression of basic fibroblast growth factor (bFGF),
reduces angiogenesis and thus inhibits tumor growth in
the bladder wall [20]. Therefore, FGFR3 may promote
the development of bladder cancer by regulating cell
division, response to type I interferon signaling, and
blood vessel morphogenesis.
To gain insight into the oncogenic mechanism of
FGFR3 in bladder cancer, we constructed FGFR3-related
molecular networks. First, a FGFR3-centered PPI net-
work was generated and KIAA1377, POLA2, FGFR3,
EPHA4, and KRT8 were the hub genes. KIAA1377, also
known as Cep126, regulates microtubule organization at
the centrosome by modulating the transport of pericen-
triolar satellites [21]. Centrosome takes vital roles in
several fundamental cellular functions, including cell
division. POLA2, encoding the B-subunit of DNA poly-
merase α, has been reported to be involved in cell prolif-
eration by mediating DNA replication, recombination,
and repair [22]. EPHA4, a member of the EPH receptors,
is closely related to tumor progression [23]. But based
on the previous studies, the investigations of relation-
ships among these hub genes were still absent. The re-
searches of these genes were only concentrated on
bioinformatics, except that EPHA4 has been confirmed
to interact with FGFR3 in vitro [24]. Thus, it was very
Fig. 1 The FGFR3-centered protein–protein interaction network. The pink nodes represent upregulated genes, and yellow nodes represent
downregulated genes




Average shortest Betweenness Degree
Path length Centrality
KIAA1377 1.83333333 0.70873016 18
POLA2 2.44444444 0.27222222 7
FGFR3 1.80555556 0.61746032 7
KRT8 2.55555556 0.21269841 5
EPHA4 2.61111111 0.16190476 4
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essential to explore the correlations among FGFR3,
KIAA1377, POLA2, and EPHA4 in bladder cancer, as
well as other cancers or diseases. Next, we predicted sev-
eral regulators and constructed a regulatory network
based on the PPI network. Total 17 miRNAs and 6 TFs
were involved. Among these TFs, TP53 is a well-known
tumor suppressor gene while MITF (microphthalmia-as-
sociated transcription factor) is an oncogene [25]. ATF2
(activating transcription factor 2) and CREB1 (CAMP
responsive element binding protein 1) are both CREB-
related proteins and share the same cAMP responsive
element sequence. They are also involved in cancer pro-
gression [26]. From the regulatory, we found that 2 miR-
NAs, hsa-miR-100 and hsa-miR-99a, directly interacted
with FGFR3. Song et al. have found the aberrant expres-
sion of these 2 miRNAs in bladder cancer by microarray
analysis of 25 cases of bladder urothelial carcinomas and
adjacent normal bladder tissue [27]. Moreover, in fact,
Fig. 2 FGFR3-related regulatory network. The pink and yellow nodes represent upregulated and downregulated genes, respectively. The square
and triangle nodes represent miRNAs and transcription factors, respectively. The arrows represent regulatory relationships between the differentially
expressed genes and miRNAs while the dotted line represents regulatory relationships between differentially expressed genes and transcription factors
Table 3 The genes significantly correlated with the prognosis
of bladder cancer patients





Table 4 Multivariate analysis result of 4 genes related to the
prognosis of bladder cancer
Gene p value OR 95% CI
HMOX2 0.808 0.895 0.366–2.19
CSTF2 0.005 0.195 0.062–0.614
POLA1 0.536 0.685 0.206–2.271
EFNB2 0.030 2.975 1.111–7.968
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the negative regulation of FGFR3 by mir-100 has been
demonstrated in clear cell ovarian cancer cells [28].
Thus, the above molecules may be responsible for the
carcinogenesis of FGFR3 in bladder cancer.
In addition to the molecule mechanism how FGFR3
contributes to the bladder cancer progression, we tried
to explore the clinical value of FGFR3. Thus, we
screened the bladder cancer recurrence-related genes
from the FGFR3-centered PPI network. The results indi-
cated that patients with high expression level of CSTF2
and POLA1 showed relative favorable prognosis. How-
ever, HMOX2 and EFNB2 may be the risk factors of
bladder cancer. CSTF2 encodes a nuclear protein which
contains a ribonucleoprotein-type binding domain in the
N-terminal region. There is a significant correlation
between CSTF2 and poor prognosis for lung cancer
patients [29]. POLA1, encoding the catalytic subunit of
DNA polymerase, is responsible for the initiation of
DNA replication. Inducible HOMX1 and constitutive
HOMX2 are 2 structurally related isozymes that com-
pose heme oxygenase. The expression level of HOMX1
is associated with cervical lymph node metastasis of
tongue squamous cell carcinomas [30]. EFNB2 has been
evidenced to be the prognostic maker for esophageal
squamous cell carcinoma [31]. In current study, we re-
vealed that there were correlations between these 4
genes and the prognosis for patients with bladder can-
cer. The results further confirmed that the genes in the
PPI network may be responsible for the carcinogenesis
of FGFR3 in bladder cancer.
Conclusions
In conclusion, we analyzed gene expression profiles of
the bladder cancer cell line RT112 with or without
depletion of FGFR3 and conducted further analyses
using a computational bioinformatics approach based on
the publicly available data. This study provided some in-
sights on the mechanism underlying the carcinogenesis
of FGFR3 in bladder cancer. However, further experi-
mental studies are needed.
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Fig. 3 Kaplan–Meier survival curves of patients with bladder cancer according to the expression of HMOX2, CSTF2, POLA1, and EFNB2
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